Synlogic is merging with private biotech Caldera Therapeutics in an all-stock deal that will take Caldera public and fund its lead drug for inflammatory bowel disease.

Both companies become subsidiaries of a new Caldera Therapeutics holding company trading on Nasdaq as CALD. Caldera shareholders will own 62.8%, private-placement investors 34.9%, and existing Synlogic shareholders just 2.3%.

A concurrent private placement brings in $278 million gross, backed by Atlas Venture, Bain Capital Life Sciences, Blackstone, Janus Henderson, venBio Partners and Wellington Management.

What a reverse merger accomplishes

The 2.3% figure defines the transaction. Synlogic shareholders retain a token stake because what is being acquired is the public listing rather than the business.

A reverse merger lets a private company become publicly traded without an IPO. It avoids the underwriting process, the roadshow and the market-timing risk of pricing an offering, and it can be completed when IPO conditions are unfavourable.

The route exists because a listed shell — a company whose programmes have failed but whose stock exchange listing, shareholder base and reporting infrastructure remain — has residual value to someone who wants those things.

The financing is what makes it work. $278 million raised alongside the merger is the actual capital event; the merger supplies the vehicle to hold it.

The lead programme

The centrepiece is CLD-423, a bispecific antibody targeting TL1A and IL-23p19 simultaneously, for ulcerative colitis, Crohn’s disease and other immune-mediated conditions.

Why those two targets

The combination reflects where inflammatory bowel disease treatment has arrived.

IL-23 is established. Antibodies blocking it are approved and effective in both major forms of IBD, working by suppressing a pathway that drives inflammatory T-cell responses in the gut. Targeting the p19 subunit specifically avoids interfering with a related cytokine sharing the other subunit.

TL1A is newer and has attracted substantial investment after mid-stage results suggested it addresses fibrosis as well as inflammation. Fibrosis — scarring that narrows the bowel — is a major cause of surgery in Crohn’s disease and is not addressed by controlling inflammation alone, so a drug affecting it would fill a genuine gap.

Combining them targets two independent mechanisms rather than reinforcing one, which is the stronger rationale for a bispecific.

The ceiling problem in IBD

The reason to pursue combinations at all is that single-agent biologics plateau.

Across mechanisms and generations, remission rates in trials have clustered in a similar range, with a substantial proportion of patients not responding adequately to any individual drug. Adding new single targets has not broken through that ceiling.

The hypothesis is that the disease involves multiple simultaneous pathways, so blocking one leaves others operating. Combination therapy addresses that, and a bispecific delivers it in one molecule — simpler to dose and to price than two separate biologics, and safer to develop than a free combination whose components could be varied.

Where it stands

CLD-423 is in a Phase 1 study in healthy volunteers in Australia that began in January 2026, described as generally well tolerated with no dose-limiting toxicities so far.

Healthy-volunteer studies establish safety and pharmacokinetics; they say nothing about efficacy, since the participants have no disease. Australia is a common location for such studies because of an established trial infrastructure and research incentives.

What comes next

Management intends to advance CLD-423 into Phase 2 for IBD while exploring additional immune-mediated indications. Cash on hand plus the placement proceeds are expected to fund operations through 2029. The deal is expected to close by early 2027.

“These transactions provide the capital and public company platform to advance our vision as we move into Phase 2 development in IBD,” said Caldera chief executive Praveen Tipirneni.

What happened to Synlogic

The company supplying the listing is worth a note, because its trajectory illustrates why shells become available.

Synlogic pursued synthetic biology as medicine: engineering live bacteria to perform therapeutic functions in the gut. Its lead programmes addressed rare metabolic disorders, using modified organisms designed to consume a compound that patients cannot metabolise, reducing the amount absorbed.

The concept was genuinely novel and attracted substantial investment. It ran into the difficulty that engineered bacteria must survive gut conditions, function consistently across variable microbiomes, and act at a rate sufficient to change blood levels of a metabolite — a demanding set of requirements. The lead programme was discontinued after disappointing results.

What remains after such a failure is a listed entity with cash, no viable pipeline and shareholders holding a stock that reflects that. A reverse merger converts the residual listing into value for those shareholders, small though 2.3% is, and gives a private company a route to public markets — which is why the structure recurs whenever a well-funded private biotech meets a failed public one.

A runway to 2029 for a company entering Phase 2 is reasonable rather than generous — IBD trials require endoscopic assessment and lengthy treatment periods, and read out slowly. Business news, not investment advice.